GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Cyclically Adjusted PB Ratio

KURA (Kura Oncology) Cyclically Adjusted PB Ratio : 0.93 (As of May. 29, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Kura Oncology's current share price is $5.55. Kura Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $5.95. Kura Oncology's Cyclically Adjusted PB Ratio for today is 0.93.

The historical rank and industry rank for Kura Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:

KURA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.94   Med: 1.22   Max: 1.48
Current: 0.95

During the past years, Kura Oncology's highest Cyclically Adjusted PB Ratio was 1.48. The lowest was 0.94. And the median was 1.22.

KURA's Cyclically Adjusted PB Ratio is ranked better than
59.49% of 669 companies
in the Biotechnology industry
Industry Median: 1.49 vs KURA: 0.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kura Oncology's adjusted book value per share data for the three months ended in Mar. 2025 was $4.511. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.95 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kura Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kura Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology Cyclically Adjusted PB Ratio Chart

Kura Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.47

Kura Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 3.30 1.47 1.11

Competitive Comparison of Kura Oncology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Kura Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Cyclically Adjusted PB Ratio falls into.


;
;

Kura Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kura Oncology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.55/5.95
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Kura Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.511/134.9266*134.9266
=4.511

Current CPI (Mar. 2025) = 134.9266.

Kura Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 1.768 100.392 2.376
201512 3.842 99.792 5.195
201603 3.559 100.470 4.780
201606 3.278 101.688 4.349
201609 2.980 101.861 3.947
201612 2.662 101.863 3.526
201703 2.349 102.862 3.081
201706 2.041 103.349 2.665
201709 2.952 104.136 3.825
201712 2.643 104.011 3.429
201803 3.742 105.290 4.795
201806 3.368 106.317 4.274
201809 4.593 106.507 5.819
201812 4.220 105.998 5.372
201903 3.918 107.251 4.929
201906 5.457 108.070 6.813
201909 5.157 108.329 6.423
201912 4.821 108.420 6.000
202003 4.473 108.902 5.542
202006 5.735 108.767 7.114
202009 5.413 109.815 6.651
202012 9.229 109.897 11.331
202103 8.843 111.754 10.677
202106 8.425 114.631 9.917
202109 8.026 115.734 9.357
202112 7.610 117.630 8.729
202203 7.147 121.301 7.950
202206 6.725 125.017 7.258
202209 6.273 125.227 6.759
202212 6.152 125.222 6.629
202303 5.774 127.348 6.118
202306 6.200 128.729 6.499
202309 5.790 129.860 6.016
202312 5.343 129.419 5.570
202403 6.630 131.776 6.789
202406 6.099 132.554 6.208
202409 5.451 133.029 5.529
202412 5.288 133.157 5.358
202503 4.511 134.927 4.511

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kura Oncology  (NAS:KURA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kura Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kura Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kura Oncology Business Description

Traded in Other Exchanges
Address
12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Executives
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas James Doyle officer: SVP, Finance & Accounting C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford officer: Chief Operating Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale officer: Chief Medical Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Troy Edward Wilson director, officer: President and CEO C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thomas Malley director C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Kirsten Flowers officer: Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer director 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Marc Grasso officer: CFO, CBO C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell officer: Acting Chief Medical Officer C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540